Unknown PHASE1 INTERVENTIONAL 1-arm NCT03001544

Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer (TS23Phase1a)

Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (α2AP) Monoclonal Antibody TS23 in Healthy Human Volunteers

Sponsor: Translational Sciences, Inc.

Conditions Cerebral Ischemia Myocardial Infarction Pulmonary Embolism Thrombosis Venous Thrombosis

Interventions TS23

Updated 7 times since 2017 Last updated: Dec 20, 2016 Started: Jul 31, 2015 Primary completion: Jun 30, 2016 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03001544, this PHASE1 trial focuses on Cerebral Ischemia and Myocardial Infarction and remains ongoing. Sponsored by Translational Sciences, Inc., it has been updated 7 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2019 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status
Jun 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Translational Sciences, Inc.

Data source: Translational Sciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.